Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

The effect of PS-341 on pulmonary vascular remodeling in high blood flow-induced pulmonary hypertension.

Zhang X, Wang ZS, Luan Y, Lin M, Zhu XB, Ma Y, Zhang ZH, Wang YB.

Int J Mol Med. 2014 Jan;33(1):105-10. doi: 10.3892/ijmm.2013.1562. Epub 2013 Nov 21.

PMID:
24270576
2.

Proteasome inhibitor PS-341 attenuates flow-induced pulmonary arterial hypertension.

Wang YY, Luan Y, Zhang X, Lin M, Zhang ZH, Zhu XB, Ma Y, Wang YB.

Clin Exp Med. 2014 Aug;14(3):321-9. doi: 10.1007/s10238-013-0244-7. Epub 2013 Jun 16.

PMID:
23771811
3.

[Effects of hydrogen sulfide on vascular inflammation in pulmonary hypertension induced by high pulmonary blood flow: experiment with rats].

Jin HF, Liang C, Liang JM, Tang CS, DU JB.

Zhonghua Yi Xue Za Zhi. 2008 Aug 19;88(32):2235-9. Chinese.

PMID:
19087668
4.

The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.

Wang H, Wang X, Li Y, Liao A, Fu B, Pan H, Liu Z, Yang W.

Pharmazie. 2012 Feb;67(2):187-92.

PMID:
22512091
5.

Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.

Li C, Chen S, Yue P, Deng X, Lonial S, Khuri FR, Sun SY.

J Biol Chem. 2010 May 21;285(21):16096-104. doi: 10.1074/jbc.M109.072694. Epub 2010 Mar 24.

6.

Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.

Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB, Younes A.

Clin Cancer Res. 2004 May 1;10(9):3207-15. Erratum in: Clin Cancer Res. 2014 Jun 1;20(11):3044.

7.

[The proteasome inhibitor MG132 attenuates skeletal muscle atrophy in a rat model of chronic obstructive pulmonary disease].

Ma BM, Liu ZH, Liang ZK, Guan LJ, Wang XL.

Zhonghua Jie He He Hu Xi Za Zhi. 2013 Jun;36(6):441-6. Chinese.

PMID:
24103208
8.

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC.

Blood. 2009 Jul 30;114(5):1046-52. doi: 10.1182/blood-2009-01-199604. Epub 2009 May 12.

9.

Inhibition of nuclear factor-κB in the lungs prevents monocrotaline-induced pulmonary hypertension in mice.

Li L, Wei C, Kim IK, Janssen-Heininger Y, Gupta S.

Hypertension. 2014 Jun;63(6):1260-9. doi: 10.1161/HYPERTENSIONAHA.114.03220. Epub 2014 Mar 10.

10.

[Mechanism by which hydrogen sulfide regulates pulmonary vascular structural remodeling induced by high pulmonary blood flow in rats].

Li XH, Du JB, Bu DF, Tang CS.

Zhonghua Er Ke Za Zhi. 2006 Dec;44(12):941-5. Chinese.

PMID:
17254467
12.

Therapeutic effects of baicalin on monocrotaline-induced pulmonary arterial hypertension by inhibiting inflammatory response.

Luan Y, Chao S, Ju ZY, Wang J, Xue X, Qi TG, Cheng GH, Kong F.

Int Immunopharmacol. 2015 May;26(1):188-93. doi: 10.1016/j.intimp.2015.01.009. Epub 2015 Jan 16.

PMID:
25601497
13.

Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.

Juvekar A, Manna S, Ramaswami S, Chang TP, Vu HY, Ghosh CC, Celiker MY, Vancurova I.

Mol Cancer Res. 2011 Feb;9(2):183-94. doi: 10.1158/1541-7786.MCR-10-0368. Epub 2011 Jan 11.

14.

Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.

Hosokawa S, Haraguchi G, Sasaki A, Arai H, Muto S, Itai A, Doi S, Mizutani S, Isobe M.

Cardiovasc Res. 2013 Jul 1;99(1):35-43. doi: 10.1093/cvr/cvt105. Epub 2013 Apr 30.

PMID:
23631839
15.

Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.

Tamatani T, Takamaru N, Hara K, Kinouchi M, Kuribayashi N, Ohe G, Uchida D, Fujisawa K, Nagai H, Miyamoto Y.

Int J Oncol. 2013 Mar;42(3):935-44. doi: 10.3892/ijo.2013.1786. Epub 2013 Jan 22.

PMID:
23340716
16.

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.

Hideshima H, Yoshida Y, Ikeda H, Hide M, Iwasaki A, Anderson KC, Hideshima T.

Int J Oncol. 2014 Apr;44(4):1171-6. doi: 10.3892/ijo.2014.2273. Epub 2014 Jan 23.

17.

Simvastatin has beneficial effect on pulmonary artery hypertension by inhibiting NF-κB expression.

Liu ZQ, Liu B, Yu L, Wang XQ, Wang J, Liu HM.

Mol Cell Biochem. 2011 Aug;354(1-2):77-82. doi: 10.1007/s11010-011-0807-4. Epub 2011 Apr 5.

PMID:
21465237
18.

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA, Berenson JR.

Clin Cancer Res. 2003 Mar;9(3):1136-44.

19.

Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.

Takigawa N, Vaziri SA, Grabowski DR, Chikamori K, Rybicki LR, Bukowski RM, Ganapathi MK, Ganapathi R, Mekhail T.

Anticancer Res. 2006 May-Jun;26(3A):1869-76.

Supplemental Content

Support Center